# CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

> **NCT07008872** · NA · NOT_YET_RECRUITING · sponsor: **Qi deng** · enrollment: 40 (estimated)

## Conditions studied

- CD7+ Lymphoma
- CD7+ Acute Leukemia

## Interventions

- **BIOLOGICAL:** CD7 CART

## Key facts

- **NCT ID:** NCT07008872
- **Lead sponsor:** Qi deng
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07008872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07008872, "CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07008872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*